- Home
- ESPR vs ZVRA Comparison
ESPR vs ZVRA Comparison
Compare ESPR & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- ZVRA
- Stock Information
- Founded
- ESPR 2008
- ZVRA 2006
- Country
- ESPR United States
- ZVRA United States
- Employees
- ESPR N/A
- ZVRA N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- ESPR Health Care
- ZVRA Health Care
- Exchange
- ESPR Nasdaq
- ZVRA Nasdaq
- Market Cap
- ESPR 456.6M
- ZVRA 473.6M
- IPO Year
- ESPR 2013
- ZVRA 2015
- Fundamental
- Price
- ESPR $2.52
- ZVRA $9.59
- Analyst Decision
- ESPR Buy
- ZVRA Strong Buy
- Analyst Count
- ESPR 3
- ZVRA 7
- Target Price
- ESPR $8.17
- ZVRA $21.20
- AVG Volume (30 Days)
- ESPR 5.2M
- ZVRA 709.1K
- Earning Date
- ESPR 11-07-2024
- ZVRA 11-12-2024
- Dividend Yield
- ESPR N/A
- ZVRA N/A
- EPS Growth
- ESPR N/A
- ZVRA N/A
- EPS
- ESPR N/A
- ZVRA N/A
- Revenue
- ESPR $295,451,000.00
- ZVRA $24,489,000.00
- Revenue This Year
- ESPR $198.22
- ZVRA N/A
- Revenue Next Year
- ESPR $25.83
- ZVRA $318.48
- P/E Ratio
- ESPR N/A
- ZVRA N/A
- Revenue Growth
- ESPR 187.12
- ZVRA 47.85
- 52 Week Low
- ESPR $1.16
- ZVRA $4.20
- 52 Week High
- ESPR $3.40
- ZVRA $9.64
- Technical
- Relative Strength Index (RSI)
- ESPR 64.07
- ZVRA 67.47
- Support Level
- ESPR $2.02
- ZVRA $8.32
- Resistance Level
- ESPR $2.60
- ZVRA $9.21
- Average True Range (ATR)
- ESPR 0.19
- ZVRA 0.54
- MACD
- ESPR 0.02
- ZVRA 0.04
- Stochastic Oscillator
- ESPR 89.04
- ZVRA 96.94
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.